All In Biotech

Drug Trial Radar · NCT06161974

Study of Olutasidenib and Temozolomide in HGG

Phase 2 Study of Olutasidenib With Temozolomide as Maintenance Therapy in Pediatric and Young Adult Patients Newly Diagnosed With High-Grade Glioma (HGG), Including Diffuse Intrinsic Pontine Glioma (DIPG), Which Harbor IDH1 Mutations

Last checked: Nov 20, 2026Latest source record: Sep 1, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

60

Planned (sponsor's estimate)

Start

Feb 1, 2025

Primary completion

Jun 2029

Study completion Jun 2035

Sponsor

Lead sponsor
Rigel PharmaceuticalsIndustry
Sponsor type
Industry
Collaborators
Nationwide Children's Hospital
First posted
Dec 8, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 12 years, up to 39 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The goal of this study is to determine the efficacy of the study drug olutasidenib to treat newly diagnosed pediatric and young adult patients with a high-grade glioma (HGG) harboring an IDH1 mutation. The main question the study aims to answer is whether the combination of olutasidenib and temozolomide (TMZ) can prolong the life of patients diagnosed with an IDH-mutant HGG.

Conditions

  • High Grade Glioma
  • Astrocytoma
  • Astrocytoma, Grade III
  • Astrocytoma, Grade IV
  • Diffuse Intrinsic Pontine Glioma
  • WHO Grade III Glioma
  • WHO Grade IV Glioma
  • Metastatic Brain Tumor
  • Diffuse Midline Glioma, H3 K27M-Mutant
  • Thalamus Tumor
  • Spinal Tumor
  • IDH1 Mutation
  • IDH1 R132
  • IDH1 R132C
  • IDH1 R132H
  • IDH1 R132S
  • IDH1 R132G
  • IDH1 R132L
  • Oligodendroglioma

Interventions

  • Olutasidenib + TMZDrug

    Olutasidenib 150 mg PO BID + Temozolomide 200 mg/m2 PO QD

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Establish the RP2D of Olutasidenib and Temozolomide (Feasibility cohort)Time frame: Completion of cycle 1 (28 days) for 6-24 patients
  2. Assess Progression-Free Survival (PFS) in Grade 3 IDH1-mutant Astrocytoma (Stratum A)Time frame: From date of diagnosis until date of Progressive Disease or death due to any cause or date of last follow-up, assessed up 24 months
  3. Maximum plasma concentration [Cmax] of OlutasidenibTime frame: From Day 1 of treatment until date of first documented progression or date of death from any cause, whichever comes first, assessed up to 24 months

Locations

20 sites in 7 countries. Site status is shown where the registry gives one.

  • Children's Hospital Colorado

    Aurora, Colorado · Not yet recruiting

  • Children's National Medical Center

    Washington D.C., District of Columbia · Not yet recruiting

  • University of Miami Hospital and Clinics

    Miami, Florida · Recruiting

  • Ann & Robert H. Lurie Children's Hospital of Chicago

    Chicago, Illinois · Recruiting

  • Susan Chi

    Boston, Massachusetts · Not yet recruiting

  • Duke University Health System

    Durham, North Carolina · Recruiting

  • Cincinnati Children's Hospital Medical Center

    Cincinnati, Ohio · Recruiting

  • Nationwide Children's Hospital

    Columbus, Ohio · Recruiting

  • Children's Hospital of Philadelphia

    Philadelphia, Pennsylvania · Not yet recruiting

  • Texas Children's Hospital

    Houston, Texas · Not yet recruiting

  • Seattle Children's Hospital

    Seattle, Washington · Recruiting

  • Sydney Children's Hospital

    Randwick, New South Wales, Australia · Recruiting

  • Queensland Children's Hospital

    South Brisbane, Queensland, Australia · Not yet recruiting

  • Perth Children's Hospital

    Perth, Western Australia, Australia · Recruiting

  • The Hospital for Sick Children (SickKids)

    Toronto, Ontario, Canada · Not yet recruiting

  • Montreal Children's Hospital

    Montreal, Quebec, Canada · Not yet recruiting

  • Hopp Children's Cancer Center at NCT Heidelberg (KiTZ)

    Heidelberg, Baden-Wurttemberg, Germany · Not yet recruiting

  • Princess Máxima Center

    Utrecht, Netherlands · Not yet recruiting

  • Starship Children's Hospital

    Auckland, Grafton, New Zealand · Not yet recruiting

  • Great Ormond Street Hospital

    London, United Kingdom · Not yet recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.